1

2
Barry Austin Gusterson, Mark Roger Crompton, Philip John Mitchell, Karen Tracey Barker, Taherah Kamalati, Martin John Page, Paul Spence: BRK protein tyrosine kinase and encoding nucleic acid. Glaxo Wellcome, Nixon & Vanderhye P C, April 18, 2000: US06051221

The invention relates to a novel tyrosine kinase designated brk and the use of this tyrosine kinase in the development of diagnostic and therapeutic approaches to cancer. The novel tyrosine kinase was isolated from a human metastatic breast tumor using a PCR based differential screening approach and ...


3
Herath Mudiyanselage Athula Chandrasiri Herath, Michael John O Hare, Martin John Page, Rajesh Bhikhu Parekh, Michael Derek Waterfield: Klauber & Jackson, April 3, 2003: US20030064419-A1

The present invention relates to the identification of proteins and protein isoforms that are associated with breast cancer and its onset and development, and of genes encoding the same, and to their use for e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, as well as for drug ...


4
Timothy Pietro Suren PERERA, Matthias Luc A Versele, Martin John Page: Vegfr3 inhibitors. Philip S Johnson, Johnson & Johnson, September 11, 2008: US20080219975-A1

The present invention relates to the use of some of the macrocyclic quinazoline derivatives described in PCT publication WO2004/105765 as inhibitors of VEGFR3 mediated biological activities, especially those activities which are mediated by VEGFR3 ligands VEGF-C and/or VEGF-D.


5
Eddy Jean Edgard FREYNE, Michel Marie Francois Janicot, Martin John Page, Timothy Pietro Suren Perera: Use of mtki 1 for treating or preventing brain cancer. Philip S Johnson, Johnson & Johnson, June 26, 2008: US20080153853-A1

The present invention is concerned with the finding that some the macrocyclic quinazoline derivative 4,6-ethanediylidenepyrimido[4,5-b][6,1,12]benzoxadiazacyclo-pentadecine, 17-bromo-8,9,10,11,12,13,14,19-octahydro-20-methoxy-13-methyl-, described as compound 22 in PCT publication W02004/105765, is ...


6
Herath Mudiyanselage Athula Chandrasiri Herath, Martin John Page: Proteins and genes for diagnosis and treatment of ErbB2-related cancer. Klauber & Jackson, October 14, 2004: US20040203022-A1

The present invention relates to the identification of polypeptides, proteins and protein isoforms that are associated with ErbB-2 related cancer and its onset and development, of genes encoding the same, and to their use for e.g., clinical screening, diagnosis, prognosis, therapy and prophylaxis, a ...


7
Janine Arts, Peter Willem Jan Hellemans, Michel Marie Francois Janicot, Martin John Page: Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors. Philip S Johnson, Johnson & Johnson, December 17, 2009: US20090312284-A1

The present invention is concerned with combinations of a proteasome inhibitor and a histone deacetylase inhibitor with combined activity on class-I and class-IIb histone deacetylases, for inhibiting the growth of tumor cells, useful in the treatment of cancer.


8
Janine Arts, Peter Willem Jan Hellemans, Michel Marie Francois Janicot, Martin John Page: Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors. Philip S Johnson, Johnson & Johnson, October 29, 2009: US20090270419-A1

The present invention is concerned with combinations of a proteasome inhibitor and a class-I specific histone deacetylase inhibitor for inhibiting the growth of tumor cells, useful in the treatment of cancer.